Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2009 Oct 1;69(19):7603-11. doi: 10.1158/0008-5472.CAN-09-2066. Epub 2009 Sep 8.

Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.

Author information

1
Departments of Cancer Biology and Pathology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, USA.

Abstract

Protein kinase Ciota (PKCiota) is an oncogene required for maintenance of the transformed phenotype of non-small cell lung cancer cells. However, the role of PKCiota in lung tumor development has not been investigated. To address this question, we established a mouse model in which oncogenic Kras(G12D) is activated by Cre-mediated recombination in the lung with or without simultaneous genetic loss of the mouse PKCiota gene, Prkci. Genetic loss of Prkci dramatically inhibits Kras-initiated hyperplasia and subsequent lung tumor formation in vivo. This effect correlates with a defect in the ability of Prkci-deficient bronchioalveolar stem cells to undergo Kras-mediated expansion and morphologic transformation in vitro and in vivo. Furthermore, the small molecule PKCiota inhibitor aurothiomalate inhibits Kras-mediated bronchioalveolar stem cell expansion and lung tumor growth in vivo. Thus, Prkci is required for oncogene-induced expansion and transformation of tumor-initiating lung stem cells. Furthermore, aurothiomalate is an effective antitumor agent that targets the tumor-initiating stem cell niche in vivo. These data have important implications for PKCiota as a therapeutic target and for the clinical use of aurothiomalate for lung cancer treatment.

PMID:
19738040
PMCID:
PMC2756303
DOI:
10.1158/0008-5472.CAN-09-2066
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center